Get the Stockscreener App
106.34
7.87%
-9.09
Pre-market:
105.51
-0.83
-0.78%
Icon Plc stock is traded at $106.34, with a volume of 2.32M.
It is down -7.87% in the last 24 hours and up +5.97% over the past month.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.
See More
Previous Close:
$115.43
Open:
$107.5
24h Volume:
2.32M
Relative Volume:
1.32
Market Cap:
$8.12B
Revenue:
$8.10B
Net Income/Loss:
$599.48M
P/E Ratio:
14.38
EPS:
7.3969
Net Cash Flow:
$971.25M
1W Performance:
-7.99%
1M Performance:
+5.97%
6M Performance:
-40.92%
1Y Performance:
-25.70%
1-Day Range:
$104.03
$110.10
1-Week Range:
$104.03
$121.03
52-Week Range:
$66.57
$211.00
Icon Plc Stock (ICLR) Company Profile
Compare ICLR vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
106.34 | 8.80B | 8.10B | 599.48M | 971.25M | 7.3969 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-26-26 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Feb-23-26 | Upgrade | Jefferies | Hold → Buy |
| Feb-18-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-17-26 | Downgrade | Rothschild & Co Redburn | Buy → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-12-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-08-26 | Downgrade | Truist | Buy → Hold |
| Dec-15-25 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
A Look at Icon PLC (ICLR) After 7.9% Decline -- GF Value $243.03 vs Price $106.34 - GuruFocus
ICON (ICLR) slides as investors stay cautious ahead of delayed results tied to accounting review - Quiver Quantitative
Icon (NASDAQ:ICLR) Shares Gap DownShould You Sell? - MarketBeat
Pre-Market Movement | Icon PLC Falls Nearly 7% in Pre-Market Trading - 富途牛牛
Is ICON plc (ICLR) stock cheap relative to earnings growth | ICON plc Posts 1.2% EPS Miss On Solid Quarterly Revenue - Xã Thanh Hà
M&T Bank Corp Has $31.50 Million Holdings in Icon Plc $ICLR - MarketBeat
16,248 Shares in Icon Plc $ICLR Purchased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
ICLR (ICON plc Ordinary Shares) falls 0.79% following Q3 2025 slight EPS miss and modest 2% year over year revenue growth.Operating Margin - Cổng thông tin điện tử tỉnh Tây Ninh
Icon (ICLR) to Release Quarterly Earnings on Wednesday - MarketBeat
Icon Plc (NASDAQ:ICLR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
ICON plc options imply 11.5% move in share price post-earnings - TipRanks
Hudson Edge Investment Partners Inc. Has $47.46 Million Position in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR) Stock Analysis: Potential Upside with Strategic Global Reach Captivates Investors - DirectorsTalk Interviews
Icon PLC (MEX:ICLRN) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
MEX:ICLRN EV-to-EBIT: 13.38 — 37% Below Median - GuruFocus
Icon PLC (MEX:ICLRN) Stock Price & 30 Year Financial Data - GuruFocus
Icon Plc $ICLR Shares Sold by Ninety One UK Ltd - MarketBeat
Ninety One North America Inc. Purchases 12,552 Shares of Icon Plc $ICLR - MarketBeat
Icon Plc $ICLR Shares Acquired by Fisher Funds Management LTD - MarketBeat
ICON plc options imply 9.7% move in share price post-earnings - TipRanks
Barclays Maintains Icon PLC(ICLR.US) With Hold Rating, Maintains Target Price $120 - 富途牛牛
ICON plc stock (IE0005711209): Why its clinical trial dominance matters more now for U.S. investors? - AD HOC NEWS
ICON Launches New Functional Service Provision (FSP) Strategy - AOL.com
USS Investment Management Ltd's Icon PLC(ICLR) Holding History - GuruFocus
Is It Too Late to Buy Icon PLC (ICLR) After 3.0% Rally? GF Value Says Undervalued - GuruFocus
Icon Plc (NASDAQ:ICLR) Short Interest Update - MarketBeat
Timber Creek Capital Management LLC Makes New $5.65 Million Investment in Icon Plc $ICLR - MarketBeat
Is ICON (NasdaqGS:ICLR) Offering An Opportunity After Recent Share Price Volatility? - Sahm
ICON plc stock (IE0005711209): Is clinical trial demand strong enough to drive U.S. investor upside? - AD HOC NEWS
Massachusetts Financial Services Co. MA Has $429.50 Million Holdings in Icon Plc $ICLR - MarketBeat
ALTRINSIC GLOBAL ADVISORS LLC's Icon PLC(ICLR) Holding History - GuruFocus
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neogen (NEOG) - The Globe and Mail
What does insider activity suggest for ICON plc (ICLR) Stock | Price at $104.66, Down 1.92%Trending Social Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Mizuho Securities Maintains Icon PLC(ICLR.US) With Buy Rating, Cuts Target Price to $180 - 富途牛牛
Trinity Street Asset Management LLP Increases Stock Position in Icon Plc $ICLR - MarketBeat
ICON plc (ICLR) Stock Forecasts - Yahoo! Finance Canada
ICON Public Limited Company (ICLR) stock price, news, quote and history - Yahoo Finance UK
Icon Plc $ICLR Shares Acquired by Aberdeen Group plc - MarketBeat
Downgrading Icon's Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback - Morningstar
Icon: Downgrading Moat Rating to None; Yet Shares Appear Undervalued Amid Significant Pullback - Morningstar
How ICON’s AI-Focused Partnership with Advarra Could Reshape ICLR’s Clinical Trial Efficiency Narrative - simplywall.st
Healthcare Rpo Market Is Going to Boom | • ICON plc • Syneos Health • Labcorp - openPR.com
ICLR Technical Analysis & Stock Price Forecast - Intellectia AI
Stock List: Research Stocks from Around the World - GuruFocus
Fund Update: 1,985,017 ICON PLC (ICLR) Shares Added to GREENHAVEN ASSOCIATES INC Portfolio - Moomoo
Fund Update: 1,985,017 ICON PLC (ICLR) shares added to GREENHAVEN ASSOCIATES INC portfolio - Quiver Quantitative
Walter Public Investments Inc.'s Icon PLC(ICLR) Holding History - GuruFocus
A Look At ICON (ICLR) Valuation After Q1 Earnings Miss And Recent Share Price Volatility - simplywall.st
ICON PLC earnings missed by $0.02, revenue was in line with estimates - Investing.com South Africa
Icon (ICLR) Dividend-Payout-to-FFO - GuruFocus
ICLR 3-Year EBITDA Growth Rate: 28.40% — 176% Above Median - GuruFocus
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):